Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRO-SBT in children with acute bacterial infection
NCT04066621Phase 4Completed
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 4, open-label, single-arm trial of ceftriaxone + sulbactam in respiratory tract infection (RTI) and urinary tract infection (UTI), sponsored by Xiangbei Welman Pharmaceuticals. Primary endpoint: The cure rate of patients. Started Apr 2015; status: completed.
02
Drugs
ceftriaxone + sulbactam
03
Conditions
respiratory tract infection (RTI)urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT04066621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066621.